HBM Healthcare Investments (Cayman) Ltd. Reports 5.4% Ownership in ArriVent BioPharma, Inc.

HBM Healthcare Investments (Cayman) Ltd. has reported a 5.4% ownership stake in ArriVent BioPharma, Inc. as of August 8, 2025. The filing, submitted under Rule 13d-1(c), indicates that the Reporting Person beneficially owns 2,195,014 shares of Common Stock. The shares are held for investment purposes and not for influencing the control of the issuer. The voting and investment power over these shares is exercised by the board of directors of HBM Healthcare Investments (Cayman) Ltd., which includes Jean-Marc LeSieur, Richard H. Coles, Sophia Harris, Dr. Andreas Wicki, Mark Kronenfeld, M.D., and Richard Paul Woodhouse. The filing was signed by Jean-Marc LeSieur, Managing Director, on October 15, 2025.